North Carolina doctor helps treat astronaut’s blood clot during NASA mission

Stephan Moll, MD, UNC School of Medicine blood clot expert and long-time NASA enthusiast

“My first reaction when NASA reached out to me was to ask if I could visit the International Space Station to examine the patient myself,” Stephan Moll, MD, UNC School of Medicine blood clot expert and long-time NASA enthusiast said, in a written statement. “NASA told me they couldn’t get me up to space quickly enough, so I proceeded with the evaluation and treatment process from here in Chapel Hill.”

Stephan Moll, MD, professor of medicine in the UNC School of Medicine, consulted with NASA on how to treat a U.S. astronaut’s deep vein thrombosis during a mission on the International Space Station, according to officials with UNC Health Care. 

Moll was the only non-NASA physician NASA consulted when it was discovered that an astronaut aboard the ISS had a deep vein thrombosis (DVT) – or blood clot – in the jugular vein of their neck.

UNC Health Care said the astronaut’s identity is being kept anonymous for privacy reasons, so identifying information such as when this event happened is being omitted from the case study. The astronaut was two months into a six-month mission on the ISS when the DVT was discovered, they said. 

This was the first time a blood clot had been found in an astronaut in space, so there was no established method of treatment for DVT in zero gravity. Moll, a member of the UNC Blood Research Center, was called upon for his vast knowledge and treatment experience of DVT on Earth.

Moll advised NASA on what dosage of Enoxaparin would effectively treat the DVT while also lasting long enough until NASA could get a new shipment of drugs – which Moll helped select – to the ISS.

“Normally the protocol for treating a patient with DVT would be to start them on blood thinners for at least three months to prevent the clot from getting bigger and to lessen the harm it could cause if it moved to a different part of the body such as the lungs,” Moll said in a written statement. “There is some risk when taking blood thinners that if an injury occurs, it could cause internal bleeding that is difficult to stop. In either case, emergency medical attention could be needed. Knowing there are no emergency rooms in space, we had to weigh our options very carefully.”

Moll and a team of NASA doctors decided blood thinners would be the best course of treatment for the astronaut. They were limited in their pharmaceutical options, however. The ISS keeps only a small supply of various medicines on board, and there was a limited amount of the blood thinner Enoxaparin (Lovenox®) available.

Moll advised NASA on what dosage of Enoxaparin would effectively treat the DVT while also lasting long enough until NASA could get a new shipment of drugs – which Moll helped select – to the ISS.

The course of treatment with Enoxaparin – a drug delivered by an injection into the skin – lasted for around 40 days. On day 43 of the astronaut’s treatment, a supply of Apixaban (Eliquis®) – a pill taken orally – was delivered to the ISS by a supply spacecraft.

Throughout the treatment process, which lasted more than 90 days, the astronaut performed ultrasounds on their own neck with guidance from a radiology team on Earth in order to monitor the blood clot. Moll was also able to speak to the astronaut during this period through email and phone calls.

“When the astronaut called my home phone, my wife answered and then passed the phone to me with the comment, ‘Stephan, a phone call for you from space.’ That was pretty amazing,” said Moll. “It was incredible to get a call from an astronaut in space. They just wanted to talk to me as if they were one of my other patients. And, amazingly, the call connection was better than when I call my family in Germany, even though the ISS zips around Earth at 17,000 miles per hour.”

Four days before the astronaut’s journey home to Earth, they stopped taking Apixaban. Moll and his NASA counterparts made that decision because of how physically demanding and potentially dangerous the re-entry process can be for astronauts, and they did not want an injury to be exacerbated by the use of blood thinners, UNC Health Care said. The astronaut landed safely on Earth and the blood clot required no more treatment.

GET THE FOX 46 CHARLOTTE NEWS APP

“Is this something that is more common in space?” posed Moll. “How do you minimize risk for DVT? Should there be more medications for it kept on the ISS? All of these questions need answering, especially with the plan that astronauts will embark on longer missions to the moon and Mars.”

For more information, please click here